Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viral-Specific T Cells for CMV in Solid Organ Transplant Recipients
NCT03950414Phase 1Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Sep 2019
- Primary completion
- Jul 2022
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adimlecleucel in cytomegalovirus infection (CMV), sponsored by University of Wisconsin–Madison. Primary endpoints: Time of Occurence of Acute GVHD at 15 weeks, Number of infusion-related adverse events at 7 weeks and 5 more. Started Sep 2019; status: terminated.
02
Drugs
adimlecleucel
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT03950414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03950414.